Citigroup Inc Innoviva, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Innoviva, Inc. stock. As of the latest transaction made, Citigroup Inc holds 84,830 shares of INVA stock, worth $1.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

84,830

Previous 59,284 43.09%

Holding current value

$1.59 Million

Previous $972,000 68.42%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$16.33 - $20.04 $417,166 - $511,941	25,546 Added 43.09%	84,830 $1.64 Million
Q2 2024 Aug 12, 2024	BUY	$14.4 - $16.4 $22,766 - $25,928	1,581 Added 2.74%	59,284 $972,000
Q1 2024 May 10, 2024	BUY	$14.56 - $16.78 $53,464 - $61,616	3,672 Added 6.8%	57,703 $879,000
Q4 2023 Feb 09, 2024	BUY	$12.32 - $16.27 $259,237 - $342,353	21,042 Added 63.78%	54,031 $866,000
Q3 2023 Nov 09, 2023	SELL	$12.37 - $13.89 $1.43 Million - $1.6 Million	-115,546 Reduced 77.79%	32,989 $428,000
Q2 2023 Aug 10, 2023	BUY	$11.39 - $13.72 $1.03 Million - $1.24 Million	90,413 Added 155.56%	148,535 $1.89 Million
Q1 2023 May 11, 2023	BUY	$10.73 - $13.6 $83,812 - $106,229	7,811 Added 15.53%	58,122 $653,000
Q4 2022 Feb 09, 2023	SELL	$11.8 - $13.78 $25,204 - $29,434	-2,136 Reduced 4.07%	50,311 $666,000
Q3 2022 Nov 10, 2022	SELL	$11.61 - $15.22 $50,886 - $66,709	-4,383 Reduced 7.71%	52,447 $609,000
Q2 2022 Aug 10, 2022	SELL	$14.32 - $19.88 $159,983 - $222,099	-11,172 Reduced 16.43%	56,830 $839,000
Q1 2022 May 12, 2022	BUY	$15.39 - $20.25 $112,254 - $147,703	7,294 Added 12.01%	68,002 $1.32 Million
Q4 2021 Feb 10, 2022	BUY	$15.91 - $18.72 $34,158 - $40,191	2,147 Added 3.67%	60,708 $1.05 Million
Q3 2021 Nov 10, 2021	BUY	$13.06 - $17.24 $764,806 - $1.01 Million	58,561 New	58,561 $979,000

Others Institutions Holding INVA

# of Institutions

225

Shares Held

78.8M

Call Options Held

37.6K

Put Options Held

300

View Full List

About Innoviva, Inc.

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.3B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

More about INVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account